Trial Profile
Efficacy, drug survival of Biosimilar Infliximab (Ct-P13) compare to the original reference infliximab (inf) in patients with inflammatory rheumatic diseases.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Nov 2018
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 13 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism